Harriet Feilotter

Overview

My research focuses on the development of biomarkers to be used in the screening, diagnosis or treatment of huan diseases, including cancer. Because the research laboratory is closely aligned with the clinical genetics laboratory service at Kingston General Hospital, the research in the lab is geared towards clinical applications for targeted biomarkers.

Our research includes the study of DNA, RNA and protein biomarkers in diseases ranging from cancer (breast, brain, melanoma, bladder, colon, CLL) to major depression. In particular, we are currently focused on the use of circulating biomarkers such as miRNA and protein species that can be found in the plasma of patients. Profiling these molecules, and then integrating the information from mutliple types of biomarkers to provide information about disease state or likely response to therapy is the primary goal of these studies.

We make use of multiple platforms, including next generation sequencing, quantitative mass spectrometry, real time PCR and microarray to generate targeted biomarker data. We also have an emerging interest and focus in informatics, including the proper handling and storage of biomarker data, the preprocessing pipelines required to ensure high quality data, and the analytic pipelines needed to deliver an effective clinical tool.

Affiliations

2016 - OICR Associate, Transformative Pathology Group, Ontario Institute for Cancer Research (OICR).
2012 - Chief Scientific Officer, Indoc Research, Ontario Cancer Biomarker Network (OCBN).
2010 - Associate Professor, Dept. of Pathology and Molecular Medicine, Queen's University.
2010 - Member, Indoc Research, Ontario Cancer Biomarker Network (OCBN).
2007 - Director, Molecular Genetics Laboratory, Kingston General Hospital.
2007 - Service Chief, Division of Laboratory Genetics, Kingston General Hospital.
2003 - Associate Member, Cancer Research Institute, Queen's University.
2014 - 2015Genetics Consultant, St. Michael's Hospital, Toronto.
2012 - 2015Clinical Chief, Genetics, Laboratory Medicine, Eastern Health, Newfoundland.
2004 - 2010Assistant Professor, Dept. of Pathology and Molecular Medicine, Queen's University.
1998 - 2000CCMG Fellow, Kingston General Hospital.
1988 - 1989PhD research, Dept. of Microbiology, University of Oxford.
1987 - 1990PhD candidate, Dept. of Biology, Queen's University.
1984 - 1987M.Sc. candidate, Dept. of Biology, Queen's University.

Research Output

  • Wang, A., Ramjeesingh, R., Chen, C., Hurlbut, D., Hammad, N., Mulligan, L., Nicol, C., Feilotter, H. and Davey, S.
    Reduction in membraneous immunostaining of EpCAM-ICD correlates with poor patient outcome in primary colorectal adenocarcinoma.
    • In press. Current Oncology.
  • Abraham, K., Zhang, X., Vidal, R., Pare, G., Feilotter, H. and Tron, V.
    Roles for microRNA-375 in neuroendocrine differentiation and tumour suppression via Notch pathway suppression in Merkel cell carcinoma
    • In press. Am. J. Path
  • Vidal, R., Hawrysh, A., Davey, S. and Feilotter, H.
    Eligibility criteria and genetic testing results from a high-risk cohort for hereditary breast and ovarian cancer syndrome in Southeastern Ontario
    • In press. J Mol Diag.
  • Feilotter, H.E., Michel, C., Uy, P., Bathurst, L., and Davey S.
    BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.
    • PLoS One 9:e100068.
  • Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H.
    EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.